Ashish Garg – författare

This book explores the potential role of prebiotics, probiotics, and synbiotics in managing various metabolic disorders, chronic diseases, and metabolic syndromes. The initial chapter provides an overview of metabolic disorders, including their classification, symptoms, and underlying causes. Additionally, the chapter discusses the intricate signaling pathways and mechanisms through which prebiotics, probiotics, and synbiotics interact with the human body in relation to type-2 diabetes, obesity, Phenylketonuria, and Hemochromatosis. Additionally, the book highlights the potential impact of probiotics and synbiotics on oxidative stress, inflammation, lipid metabolism, and blood pressure. Furthermore, this book focuses on the gut-brain axis and how synbiotics may influence neurotransmitter metabolism. With an emphasis on the gut-microbiota axis, this book presents a compelling narrative that explores the rationality behind synbiotic use and offers a glimpse into future perspectives for managing metabolic disorders effectively. This book is intended for researchers in the fields of nutraceuticals, nanomedicine, endocrinology, nutrition, gastroenterology, and metabolic medicine who are working in the field of probiotics, prebiotics, and symbiotics for the treatment of metabolic disorders.

This book explores the potential role of prebiotics, probiotics, and synbiotics in managing various metabolic disorders, chronic diseases, and metabolic syndromes. The initial chapter provides an overview of metabolic disorders, including their classification, symptoms, and underlying causes. Additionally, the chapter discusses the intricate signaling pathways and mechanisms through which prebiotics, probiotics, and synbiotics interact with the human body in relation to type-2 diabetes, obesity, Phenylketonuria, and Hemochromatosis. Additionally, the book highlights the potential impact of probiotics and synbiotics on oxidative stress, inflammation, lipid metabolism, and blood pressure. Furthermore, this book focuses on the gut-brain axis and how synbiotics may influence neurotransmitter metabolism. With an emphasis on the gut-microbiota axis, this book presents a compelling narrative that explores the rationality behind synbiotic use and offers a glimpse into future perspectives for managing metabolic disorders effectively. This book is intended for researchers in the fields of nutraceuticals, nanomedicine, endocrinology, nutrition, gastroenterology, and metabolic medicine who are working in the field of probiotics, prebiotics, and symbiotics for the treatment of metabolic disorders.

This new volume delves into the extensive new research on inflammatory bowel disease (IBD) and gut microbiota that has led to effective therapeutic interventions. Highlighting novel methodologies and innovative treatment approaches, the book provides a comprehensive investigation of IBD, exploring the significance of gut microbiota and investigating the fundamental role of microbial imbalances in the initiation and progression of inflammatory processes as well as the prominent therapeutic consequences of restoring microbial homeostasis. From nanoparticle-based drug delivery systems that advance the bioavailability of the medicament to the use of bio-nanosensors for early detection of disease, the book covers a broad spectrum of inventions that hold potential for revolutionizing IBD treatment. The authors look at the impact of nutraceuticals, probiotics, prebiotics, functional foods, oral siRNA-based nanomedicine, and other novel drug delivery systems on gut microbiota for the management of IBD. The book also explores the role of reactive oxygen species (ROSs), superoxide dismutases (SODs), and inflammation in association with gut microbiota and IBD.

This new volume delves into the extensive new research on inflammatory bowel disease (IBD) and gut microbiota that has led to effective therapeutic interventions. Highlighting novel methodologies and innovative treatment approaches, the book provides a comprehensive investigation of IBD, exploring the significance of gut microbiota and investigating the fundamental role of microbial imbalances in the initiation and progression of inflammatory processes as well as the prominent therapeutic consequences of restoring microbial homeostasis. From nanoparticle-based drug delivery systems that advance the bioavailability of the medicament to the use of bio-nanosensors for early detection of disease, the book covers a broad spectrum of inventions that hold potential for revolutionizing IBD treatment. The authors look at the impact of nutraceuticals, probiotics, prebiotics, functional foods, oral siRNA-based nanomedicine, and other novel drug delivery systems on gut microbiota for the management of IBD. The book also explores the role of reactive oxygen species (ROSs), superoxide dismutases (SODs), and inflammation in association with gut microbiota and IBD.

This comprehensive volume covers the entire field of flavonoids by explaining their complex functions in reducing chronic metabolic illnesses, from the early stages of laboratory research to the development of therapeutic uses.

Flavonoids are plant-based substances proven to have potential medical benefits in managing chronic metabolic disorders. This book explores concepts in laboratory research and therapeutic capabilities to enhance awareness of flavonoids in a medical context.

The book begins with a thorough examination of the basic biochemical and molecular processes that underlie long-term metabolic disorders. It looks into these bioactive substances, from their natural origins to the synthesis of innovative derivatives. Analyzing both lab research and preclinical trials critically, it provides a solid basis for understanding the exciting opportunities flavonoids bring in treating metabolic diseases.

The scope of this work extends beyond theoretical domains into clinical environments. It closes the gap between bench-side findings and bedside applications by revealing the translational potential of flavonoids. It is possible to understand the practical implications and future directions of flavonoid-based therapeutics through the synthesis of evidence-based clinical studies, therapeutic approaches, and possible healthcare issues.

Readers will find the book:

Audience

This book is intended for researchers, scientists, clinicians/physicians, and public health professionals who work in pharmacology settings. The book is a vital tool for clinicians, nutritionists, and other healthcare professionals who are concerned about cutting-edge methods for dietary guidelines to gain an understanding of flavonoids and long-term metabolic disorders.

This comprehensive volume covers the entire field of flavonoids by explaining their complex functions in reducing chronic metabolic illnesses, from the early stages of laboratory research to the development of therapeutic uses.

Flavonoids are plant-based substances proven to have potential medical benefits in managing chronic metabolic disorders. This book explores concepts in laboratory research and therapeutic capabilities to enhance awareness of flavonoids in a medical context.

The book begins with a thorough examination of the basic biochemical and molecular processes that underlie long-term metabolic disorders. It looks into these bioactive substances, from their natural origins to the synthesis of innovative derivatives. Analyzing both lab research and preclinical trials critically, it provides a solid basis for understanding the exciting opportunities flavonoids bring in treating metabolic diseases.

The scope of this work extends beyond theoretical domains into clinical environments. It closes the gap between bench-side findings and bedside applications by revealing the translational potential of flavonoids. It is possible to understand the practical implications and future directions of flavonoid-based therapeutics through the synthesis of evidence-based clinical studies, therapeutic approaches, and possible healthcare issues.

Readers will find the book:

Audience

This book is intended for researchers, scientists, clinicians/physicians, and public health professionals who work in pharmacology settings. The book is a vital tool for clinicians, nutritionists, and other healthcare professionals who are concerned about cutting-edge methods for dietary guidelines to gain an understanding of flavonoids and long-term metabolic disorders.

The emerging role of gut microbiota and postbiotics has implications for the management of not only human health and diseases, but also colorectal cancer in particular, as these elements influence colorectal cancer pathogenesis, treatment, and prevention. This book bridges the gap between cutting-edge research and practical clinical applications in the management of colorectal cancer by offering a fresh perspective on potential therapeutic strategies and exploring the significance of microbiota in the oncology landscape. Chapters delve into the specific impacts of postbiotics, linking them to immune response modulation, inflammation reduction, and direct anticancer effects. Chapters also explore current and emerging therapies, including the manipulation of gut microbiota and the use of postbiotics supplements. Clinical trial results, case studies, and expert opinions are interwoven to present a realistic view of the benefits, limitations, and future prospects of these innovative therapeutic strategies.

This book is rounded out with perspectives on future research directions in this area, discussing potential next-generation therapies such as personalized medicine approaches and biotechnological advancements, and further contemplating broader implications of microbiota research on public health strategies. Informative and engaging, this book provides clinicians and researchers alike with a deeper understanding of how postbiotics can be harnessed in colorectal cancer treatment and potentially, the treatment of other cancers influenced by gut health.